Last reviewed · How we verify
Docetaxel, nedaplatin, fluorouracil
This combination regimen uses a microtubule-stabilizing taxane, a platinum-based DNA crosslinker, and an antimetabolite to inhibit cancer cell division and induce apoptosis through multiple mechanisms.
This combination regimen uses a microtubule-stabilizing taxane, a platinum-based DNA crosslinker, and an antimetabolite to inhibit cancer cell division and induce apoptosis through multiple mechanisms. Used for Gastric cancer (phase 3 investigation), Advanced solid tumors.
At a glance
| Generic name | Docetaxel, nedaplatin, fluorouracil |
|---|---|
| Also known as | DNF |
| Sponsor | Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation. Nedaplatin forms DNA crosslinks, preventing replication and transcription. Fluorouracil inhibits thymidylate synthase and is incorporated into RNA/DNA, disrupting nucleotide synthesis. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Gastric cancer (phase 3 investigation)
- Advanced solid tumors
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Mucositis
- Alopecia
Key clinical trials
- Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC (PHASE3)
- Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma (PHASE3)
- Nedaplatin in Treatment for Nasopharyngeal Carcinoma (PHASE2)
- Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma
- Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
- A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC (PHASE4)
- A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC (PHASE4)
- A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |